These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 10447577)

  • 41. Pegylated liposomal doxorubicin and cyclophosphamide in early recurrent ovarian carcinoma: phase I dose-finding study.
    Floquet A; Doussau A; Brouste V; Cany L; Dutin JP; Mathoulin-Pélissier S
    Cancer Chemother Pharmacol; 2014 Jan; 73(1):61-8. PubMed ID: 24141374
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Grade 3 liposomal-doxorubicin-induced skin toxicity in a patient following complete resolution of moderately severe sunburn.
    Markman M; Kulp B; Peterson G
    Gynecol Oncol; 2004 Aug; 94(2):578-80. PubMed ID: 15297208
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A randomized, double-blind study of pegylated liposomal doxorubicin for the treatment of AIDS-related Kaposi's sarcoma.
    Cooley T; Henry D; Tonda M; Sun S; O'Connell M; Rackoff W
    Oncologist; 2007 Jan; 12(1):114-23. PubMed ID: 17227906
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a pediatric oncology group study.
    Marina NM; Cochrane D; Harney E; Zomorodi K; Blaney S; Winick N; Bernstein M; Link MP
    Clin Cancer Res; 2002 Feb; 8(2):413-8. PubMed ID: 11839657
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prospective randomized Phase II trial of pegylated doxorubicin in the management of symptomatic hormone-refractory prostate carcinoma.
    Heidenreich A; Sommer F; Ohlmann CH; Schrader AJ; Olbert P; Goecke J; Engelmann UH
    Cancer; 2004 Sep; 101(5):948-56. PubMed ID: 15329902
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients.
    Hussein MA; Wood L; Hsi E; Srkalovic G; Karam M; Elson P; Bukowski RM
    Cancer; 2002 Nov; 95(10):2160-8. PubMed ID: 12412170
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients.
    Gorumlu G; Kucukzeybek Y; Kemal-Gul M; Karaca B; Cosan-Terek M; Karabulut B; Sanli UA; Akman L; Ozsaran A; Dikmen Y; Uslu R
    J BUON; 2008; 13(3):349-52. PubMed ID: 18979548
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phase II clinical trial of pegylated liposomal doxorubicin (JNS002) in Japanese patients with mullerian carcinoma (epithelial ovarian carcinoma, primary carcinoma of fallopian tube, peritoneal carcinoma) having a therapeutic history of platinum-based chemotherapy: a Phase II Study of the Japanese Gynecologic Oncology Group.
    Katsumata N; Fujiwara Y; Kamura T; Nakanishi T; Hatae M; Aoki D; Tanaka K; Tsuda H; Kamiura S; Takehara K; Sugiyama T; Kigawa J; Fujiwara K; Ochiai K; Ishida R; Inagaki M; Noda K
    Jpn J Clin Oncol; 2008 Nov; 38(11):777-85. PubMed ID: 18927230
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome.
    Lokich JJ; Moore C
    Ann Intern Med; 1984 Dec; 101(6):798-9. PubMed ID: 6497196
    [No Abstract]   [Full Text] [Related]  

  • 50. Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.
    Pujade-Lauraine E; Wagner U; Aavall-Lundqvist E; Gebski V; Heywood M; Vasey PA; Volgger B; Vergote I; Pignata S; Ferrero A; Sehouli J; Lortholary A; Kristensen G; Jackisch C; Joly F; Brown C; Le Fur N; du Bois A
    J Clin Oncol; 2010 Jul; 28(20):3323-9. PubMed ID: 20498395
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: a randomized, double-blind clinical trial using a canine model.
    Vail DM; Chun R; Thamm DH; Garrett LD; Cooley AJ; Obradovich JE
    Clin Cancer Res; 1998 Jun; 4(6):1567-71. PubMed ID: 9626479
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phase II study of pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients. May a new treatment schedule improve toxicity profile?
    Lorusso D; Naldini A; Testa A; D'Agostino G; Scambia G; Ferrandina G
    Oncology; 2004; 67(3-4):243-9. PubMed ID: 15557785
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Oral dexamethasone attenuates Doxil-induced palmar-plantar erythrodysesthesias in patients with recurrent gynecologic malignancies.
    Drake RD; Lin WM; King M; Farrar D; Miller DS; Coleman RL
    Gynecol Oncol; 2004 Aug; 94(2):320-4. PubMed ID: 15297168
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Severe palmoplantar erythrodysesthesia and intertrigolike eruption induced by polyethylene glycol-coated liposomal doxorubicin.
    Campanelli A; Kerl K; Lübbe J
    J Eur Acad Dermatol Venereol; 2006 Sep; 20(8):1022-4. PubMed ID: 16922969
    [No Abstract]   [Full Text] [Related]  

  • 55. Phase I/II trial of intravenous Doxil and whole abdomen hyperthermia in patients with refractory ovarian cancer.
    Alvarez Secord A; Jones EL; Hahn CA; Petros WP; Yu D; Havrilesky LJ; Soper JT; Berchuck A; Spasojevic I; Clarke-Pearson DL; Prosnitz LR; Dewhirst MW
    Int J Hyperthermia; 2005 Jun; 21(4):333-47. PubMed ID: 16019859
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective phase II study of the Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut).
    du Bois A; Pfisterer J; Burchardi N; Loibl S; Huober J; Wimberger P; Burges A; Stähle A; Jackisch C; Kölbl H; ;
    Gynecol Oncol; 2007 Dec; 107(3):518-25. PubMed ID: 17910981
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A phase I study of oral topotecan and pegylated liposomal doxorubicin (doxil) in platinum-resistant ovarian and peritoneal cancer.
    Rose PG; Smrekar M; Haba P; Fusco N; Rodriguez M
    Am J Clin Oncol; 2008 Oct; 31(5):476-80. PubMed ID: 18838885
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Liposomal doxorubicin-related palmar-plantar erythrodysesthesia (hand-foot syndrome): a case report.
    Ni C; Fang J; Qian H; Xu Q; Shen F
    J Int Med Res; 2020 Dec; 48(12):300060520974854. PubMed ID: 33356712
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993).
    Coleman RE; Biganzoli L; Canney P; Dirix L; Mauriac L; Chollet P; Batter V; Ngalula-Kabanga E; Dittrich C; Piccart M
    Eur J Cancer; 2006 May; 42(7):882-7. PubMed ID: 16520033
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pilot phase 2 trial of 4 months of maintenance pegylated liposomal Doxorubicin in patients with advanced ovarian cancer after complete response to platinum and Paclitaxel-based chemotherapy.
    DiSilvestro PA; Fisher M; Pearl ML; Buhl A; Chalas E; Valea FA
    Gynecol Obstet Invest; 2007; 63(1):1-6. PubMed ID: 16809933
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.